Neuropsychiatric systemic lupus erythematosus

Last updated
Neuropsychiatric systemic lupus erythematosus
Other namesCNS lupus, lupus cerebritis
Specialty Rheumatology, Neurology

Neuropsychiatric systemic lupus erythematosus or NPSLE refers to the neurological and psychiatric manifestations of systemic lupus erythematosus. SLE is a disease in which the immune system attacks the body's own cells and tissues. It can affect various organs or systems of the body. It is estimated that over half of people with SLE have neuropsychiatric involvement. [1]

Contents

Classification

The American College of Rheumatology (ACR) has outlined 19 syndromes that are seen in NPSLE. These syndromes encompass disorders of the central and peripheral nervous systems: [2]

Each of the 19 syndromes are also stand-alone diagnoses, which can occur with or without lupus.

The majority of cases involve the central nervous system (CNS), which consists of the brain and spinal cord. [2] The most common CNS syndromes are headache and mood disorder. [1]

Though neuropsychiatric lupus is sometimes referred to as "CNS lupus", it can also affect the peripheral nervous system (PNS). Between 10-15% of people with NPSLE have PNS involvement. [3] Mononeuropathy and polyneuropathy are the most common PNS syndromes. [1]

Other syndromes

Some neurological syndromes outside of the ACR classification may also be considered NPSLE manifestations. These include neuromyelitis optica, posterior reversible encephalopathy syndrome, small fiber neuropathy, [4] and Lambert–Eaton myasthenic syndrome. [5]

Pathogenesis

There are several possible mechanisms that underlie the nervous system manifestations of lupus. Specific syndromes may be vasculopathic, autoantibody-mediated, or inflammatory in nature.

There is evidence that the blood–brain barrier, which protects the central nervous system, is compromised in patients with NPSLE. As a result of this, autoantibodies are able to infiltrate the CNS and cause damage. [6]

Diagnosis

For diagnosis of NPSLE, it must be determined whether neuropsychiatric symptoms are indeed caused by SLE, whether they constitute a separate comorbid condition, or whether they are an adverse effect of disease treatment. In addition, onset of neuropsychiatric symptoms may happen prior to the diagnosis of lupus. [7] Due to the lack of uniform diagnostic standards, statistics about NPSLE vary widely. [8]

Tests which aid in diagnosis include MRI, electrophysiological studies, psychiatric evaluation, and autoantibody tests. [9]

Treatment

Management of neuropsychiatric lupus is similar to the management of neuropsychiatric disease in patients without lupus. Treatment depends on the underlying causes of a patient’s disease, and may include immunosuppressants, anticoagulants, and symptomatic therapy. [9]

See also

Related Research Articles

<span class="mw-page-title-main">Sjögren syndrome</span> Autoimmune disease affecting the bodys moisture-producing glands

Sjögren syndrome or Sjögren's syndrome is a long-term autoimmune disease that affects the body's moisture-producing glands, and often seriously affects other organ systems, such as the lungs, kidneys, and nervous system.

<span class="mw-page-title-main">Antinuclear antibody</span> Autoantibody that binds to contents of the cell nucleus

Antinuclear antibodies are autoantibodies that bind to contents of the cell nucleus. In normal individuals, the immune system produces antibodies to foreign proteins (antigens) but not to human proteins (autoantigens). In some cases, antibodies to human antigens are produced.

Libman–Sacks endocarditis is a form of non-bacterial endocarditis that is seen in association with systemic lupus erythematosus, antiphospholipid syndrome, and malignancies. It is one of the most common cardiac manifestations of lupus.

<span class="mw-page-title-main">Malar rash</span> Medical condition

A malar rash, also called butterfly rash, is a medical sign consisting of a characteristic form of facial rash. It is often seen in lupus erythematosus. More rarely, it is also seen in other diseases, such as pellagra, dermatomyositis, and Bloom syndrome.

<span class="mw-page-title-main">Lupus nephritis</span> Inflammation of the kidneys

Lupus nephritis is an inflammation of the kidneys caused by systemic lupus erythematosus (SLE), an autoimmune disease. It is a type of glomerulonephritis in which the glomeruli become inflamed. Since it is a result of SLE, this type of glomerulonephritis is said to be secondary, and has a different pattern and outcome from conditions with a primary cause originating in the kidney. The diagnosis of lupus nephritis depends on blood tests, urinalysis, X-rays, ultrasound scans of the kidneys, and a kidney biopsy. On urinalysis, a nephritic picture is found and red blood cell casts, red blood cells and proteinuria is found.

An autoantibody is an antibody produced by the immune system that is directed against one or more of the individual's own proteins. Many autoimmune diseases are associated with such antibodies.

Extractable nuclear antigens (ENAs) are over 100 different soluble cytoplasmic and nuclear antigens. They are known as "extractable" because they can be removed from cell nuclei using saline and represent six main proteins: Ro, La, Sm, RNP, Scl-70, Jo1. Most ENAs are part of spliceosomes or nucleosomes complexes and are a type of small nuclear ribonucleoprotein (snRNPS). The location in the nucleus and association with spliceosomes or nucleosomes results in these ENAs being associated with additional RNA and proteins such as polymerases. This quality of ENAs often makes it difficult to purify and quantify their presence for clinical use.

A systemic disease is one that affects a number of organs and tissues, or affects the body as a whole.

Mixed connective tissue disease, commonly abbreviated as MCTD, is an autoimmune disease characterized by the presence of elevated blood levels of a specific autoantibody, now called anti-U1 ribonucleoprotein (RNP) together with a mix of symptoms of systemic lupus erythematosus (SLE), scleroderma, and polymyositis. The idea behind the "mixed" disease is that this specific autoantibody is also present in other autoimmune diseases such as systemic lupus erythematosus, polymyositis, scleroderma, etc. MCTD was characterized as an individual disease in 1972 by Sharp et al., and the term was introduced by Leroy in 1980.

<span class="mw-page-title-main">Lupus erythematosus</span> Human disease

Lupus erythematosus is a collection of autoimmune diseases in which the human immune system becomes hyperactive and attacks healthy tissues. Symptoms of these diseases can affect many different body systems, including joints, skin, kidneys, blood cells, heart, and lungs. The most common and most severe form is systemic lupus erythematosus.

Betty Diamond is an American physician and researcher. She is director of the Institute of Molecular Medicine at Northwell Health's Feinstein Institute for Medical Research in Manhasset, NY. She was elected a member of the National Academy of Sciences in 2022.

<span class="mw-page-title-main">Complement 2 deficiency</span> Medical condition

Complement 2 deficiency is a type of complement deficiency caused by any one of several different alterations in the structure of complement component 2.

<span class="mw-page-title-main">Autoimmune disease</span> Disorders of adaptive immune system

An autoimmune disease is a condition that results from an anomalous response of the adaptive immune system, wherein it mistakenly targets and attacks healthy, functioning parts of the body as if they were foreign organisms. It is estimated that there are more than 80 recognized autoimmune diseases, with recent scientific evidence suggesting the existence of potentially more than 100 distinct conditions. Nearly any body part can be involved.

<span class="mw-page-title-main">Anti-dsDNA antibodies</span> Group of anti-nuclear antibodies

Anti-double stranded DNA (Anti-dsDNA) antibodies are a group of anti-nuclear antibodies (ANA) the target antigen of which is double stranded DNA. Blood tests such as enzyme-linked immunosorbent assay (ELISA) and immunofluorescence are routinely performed to detect anti-dsDNA antibodies in diagnostic laboratories. They are highly diagnostic of systemic lupus erythematosus (SLE) and are implicated in the pathogenesis of lupus nephritis.

<span class="mw-page-title-main">Lupus</span> Human autoimmune disease

Lupus, technically known as systemic lupus erythematosus (SLE), is an autoimmune disease in which the body's immune system mistakenly attacks healthy tissue in many parts of the body. Symptoms vary among people and may be mild to severe. Common symptoms include painful and swollen joints, fever, chest pain, hair loss, mouth ulcers, swollen lymph nodes, feeling tired, and a red rash which is most commonly on the face. Often there are periods of illness, called flares, and periods of remission during which there are few symptoms.

Lupus headache is a proposed, specific headache disorder in patients with systemic lupus erythematosus (SLE). Research shows that headache is a symptom commonly described by SLE patients —57% in one meta-analysis, ranging in different studies from 33% to 78%; of which migraine 31.7% and tension-type headache 23.5%. The existence of a special lupus headache is contested, although few high-quality studies are available to form definitive conclusions.

The Undifferentiated connective tissue disease (UCTD) is a disease in which the connective tissues are targeted by the immune system. It is a serological and clinical manifestation of an autoimmune disease. When there is proof of an autoimmune disease, it will be diagnosed as UCTD if the disease doesn't answer to any criterion of specific autoimmune disease. Such as systemic lupus erythematosus (SLE), la scleroderma, mixed connective tissue disease, Sjögren syndrome, systemic sclerosis, polymyositis, dermatomyositis, or the rheumatoid arthritis. This is also the case of major rheumatic diseases whose early phase was defined by LeRoy et al. in 1980 as undifferentiated connective tissue disease. The latent Lupus and the incomplete lupus are alternative terms used to describe this condition.

Anti-histone antibodies are autoantibodies that are a subset of the anti-nuclear antibody family, which specifically target histone protein subunits or histone complexes. They were first reported by Henry Kunkel, H.R. Holman, and H.R.G. Dreicher in their studies of cellular causes of lupus erythematosus in 1959–60. Today, anti-histone antibodies are still used as a marker for systemic lupus erythematosus, but are also implicated in other autoimmune diseases like Sjögren syndrome, dermatomyositis, or rheumatoid arthritis. Anti-histone antibodies can be used as a marker for drug-induced lupus.

<span class="mw-page-title-main">Anti-SSA/Ro autoantibodies</span> Type of anti-nuclear autoantibodies

Anti-SSA autoantibodies are a type of anti-nuclear autoantibodies that are associated with many autoimmune diseases, such as systemic lupus erythematosus (SLE), SS/SLE overlap syndrome, subacute cutaneous lupus erythematosus (SCLE), neonatal lupus and primary biliary cirrhosis. They are often present in Sjögren's syndrome (SS). Additionally, Anti-Ro/SSA can be found in other autoimmune diseases such as systemic sclerosis (SSc), polymyositis/dermatomyositis (PM/DM), rheumatoid arthritis (RA), and mixed connective tissue disease (MCTD), and are also associated with heart arrhythmia.

<span class="mw-page-title-main">Congenital heart block</span> Medical condition

The congenital heart block (CHB) is the heart block that is diagnosed in fetus or within the first 28 days after birth, some studies also include the diagnosis during early childhood to the definition of CHB. It refers to the disorder in the electrical conduction system within the heart muscle, which leads to the failure in pumping the blood efficiently into the aorta and the pulmonary trunk. The result of CHB can be first, second, or third-degree (complete) atrioventricular block in which no electric signals move from the atrium to the ventricles

References

  1. 1 2 3 Unterman, Avraham; Nolte, Johannes ES; Boaz, Mona; Abady, Maya; Shoenfeld, Yehuda; Zandman-Goddard, Gisele (August 2011). "Neuropsychiatric Syndromes in Systemic Lupus Erythematosus: A Meta-Analysis". Seminars in Arthritis and Rheumatism. 41 (1): 1–11. doi:10.1016/j.semarthrit.2010.08.001. ISSN   0049-0172. PMID   20965549.
  2. 1 2 Liang, Matthew H; Corzillius, Michael; Bae, Sang Cheol; Lew, Robert A; Fortin, Paul R; et al. (April 1999). "The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes". Arthritis and Rheumatism. 42 (4): 599–608. doi: 10.1002/1529-0131(199904)42:4<599::AID-ANR2>3.0.CO;2-F . ISSN   0004-3591. PMID   10211873.
  3. ↑ Kivity, Shaye; Agmon-Levin, Nancy; Zandman-Goddard, Gisele; Chapman, Joab; Shoenfeld, Yehuda (March 2015). "Neuropsychiatric lupus: a mosaic of clinical presentations". BMC Medicine. 13 (1): 43. doi: 10.1186/s12916-015-0269-8 . ISSN   1741-7015. PMC   4349748 . PMID   25858312.
  4. ↑ Bortoluzzi, Alessandra; Scirè, Carlo Alberto; Govoni, Marcello (14 March 2018). "Attribution of Neuropsychiatric Manifestations to Systemic Lupus Erythematosus". Frontiers in Medicine . 5: 68. doi: 10.3389/fmed.2018.00068 . PMC   5861139 . PMID   29594125.
  5. ↑ West, Sterling G; Hanly, John G (2019). "Lupus and the Nervous System: Clinical Aspects, Psychopathology, and Imaging". In Wallace, Daniel J; Hahn, Bevra Hannahs (eds.). Dubois' Lupus Erythematosus and Related Syndromes (Ninth ed.). Elsevier. pp. 434–456. doi:10.1016/B978-0-323-47927-1.00036-0. ISBN   978-0-323-47927-1. S2CID   80722393.
  6. ↑ Stock, Ariel D; Wen, Jing; Putterman, Chaim (December 2013). "Neuropsychiatric lupus, the blood brain barrier, and the TWEAK/Fn14 pathway". Frontiers in Immunology. 4: 484. doi: 10.3389/fimmu.2013.00484 . ISSN   1664-3224. PMC   3872310 . PMID   24400009.
  7. ↑ Bertsias, GK; Ioannidis, JPA; Aringer, M; Bollen, E; Bombardieri, S; et al. (2010). "EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs". Annals of the Rheumatic Diseases. 69 (12): 2074–2082. doi: 10.1136/ard.2010.130476 . ISSN   0003-4967. PMID   20724309.
  8. ↑ Gulinello, Maria; Wen, Jing; Putterman, Chaim (September 2012). "Neuropsychiatric Symptoms in Lupus". Psychiatric Annals. 42 (9): 322–328. doi:10.3928/00485713-20120906-05. PMC   4302271 . PMID   25620816.
  9. 1 2 Magro-Checa, Cesar; Zirkzee, Elisabeth J; Huizinga, Tom W; Steup-Beekman, Gerda M (2016). "Management of Neuropsychiatric Systemic Lupus Erythematosus: Current Approaches and Future Perspectives". Drugs. 76 (4): 459–483. doi:10.1007/s40265-015-0534-3. ISSN   0012-6667. PMC   4791452 . PMID   26809245.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.